PHI-1’s role as a cancer driver directly translates into its clinical implications, serving as both a biomarker for tumor aggressiveness and therapy resistance as well as a potential therapeutic target across multiple cancer types (Table 1). The gene discussed is PPP1R14B; the disease is cancer.